BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thaler F, Mercurio C. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next. ChemMedChem. 2014;9:523-526. [PMID: 24730063 DOI: 10.1002/cmdc.201300413] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Carbajo-García MC, García-Alcázar Z, Corachán A, Monleón J, Trelis A, Faus A, Pellicer A, Ferrero H. Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma. Fertil Steril 2021:S0015-0282(21)02135-X. [PMID: 34809976 DOI: 10.1016/j.fertnstert.2021.10.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hearn KN, Ashton TD, Acharya R, Feng Z, Gueven N, Pfeffer FM. Direct Amidation to Access 3-Amido-1,8-Naphthalimides Including Fluorescent Scriptaid Analogues as HDAC Inhibitors. Cells 2021;10:1505. [PMID: 34203745 DOI: 10.3390/cells10061505] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Mazzocchi M, Goulding SR, Wyatt SL, Collins LM, Sullivan AM, O'Keeffe GW. LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's disease. Mol Cell Neurosci 2021;115:103642. [PMID: 34119632 DOI: 10.1016/j.mcn.2021.103642] [Reference Citation Analysis]
4 Ren Y, Li S, Zhu R, Wan C, Song D, Zhu J, Cai G, Long S, Kong L, Yu W. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer. J Med Chem 2021;64:7468-82. [PMID: 34043359 DOI: 10.1021/acs.jmedchem.1c00136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wu CP, Hung CY, Lusvarghi S, Chang YF, Hsiao SH, Huang YH, Hung TH, Yu JS, Ambudkar SV. Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat. Int J Mol Sci 2021;22:2592. [PMID: 33807514 DOI: 10.3390/ijms22052592] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Mak JYW, Wu KC, Gupta PK, Barbero S, McLaughlin MG, Lucke AJ, Tng J, Lim J, Loh Z, Sweet MJ, Reid RC, Liu L, Fairlie DP. HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates. J Med Chem 2021;64:2186-204. [PMID: 33570940 DOI: 10.1021/acs.jmedchem.0c01967] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lemos M, Stefanova N. Histone Deacetylase 6 and the Disease Mechanisms of α-Synucleinopathies. Front Synaptic Neurosci 2020;12:586453. [PMID: 33041780 DOI: 10.3389/fnsyn.2020.586453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. Curr Med Chem 2020;27:2449-93. [PMID: 30332940 DOI: 10.2174/0929867325666181016163110] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
9 Hassan MM, Israelian J, Nawar N, Ganda G, Manaswiyoungkul P, Raouf YS, Armstrong D, Sedighi A, Olaoye OO, Erdogan F, Cabral AD, Angeles F, Altintas R, de Araujo ED, Gunning PT. Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting. J Med Chem 2020;63:8634-48. [PMID: 32672458 DOI: 10.1021/acs.jmedchem.0c01025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
10 De Vita S, Terracciano S, Bruno I, Chini MG. From Natural Compounds to Bioactive Molecules through NMR and In Silico Methodologies. Eur J Org Chem 2020;2020:6297-317. [DOI: 10.1002/ejoc.202000469] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Rodrigues DA, Pinheiro PDSM, Sagrillo FS, Bolognesi ML, Fraga CAM. Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. Med Res Rev 2020;40:2177-211. [DOI: 10.1002/med.21701] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
12 Dewaker V, Srivastava AK, Arora A, Prabhakar YS. Investigation of HDAC8-ligands’ intermolecular forces through molecular dynamics simulations: profiling of non-bonding energies to design potential compounds as new anti-cancer agents. Journal of Biomolecular Structure and Dynamics 2021;39:4726-51. [DOI: 10.1080/07391102.2020.1780940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Kavianpour P, Gemmell MCM, Kahlert JU, Rendina LM. Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron. ChemBioChem 2020;21:2786-91. [DOI: 10.1002/cbic.202000131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Cross JM, Blower TR, Kingdon ADH, Pal R, Picton DM, Walton JW. Anticancer Ruthenium Complexes with HDAC Isoform Selectivity. Molecules 2020;25:E2383. [PMID: 32455529 DOI: 10.3390/molecules25102383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Morgen M, Steimbach RR, Géraldy M, Hellweg L, Sehr P, Ridinger J, Witt O, Oehme I, Herbst-Gervasoni CJ, Osko JD, Porter NJ, Christianson DW, Gunkel N, Miller AK. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors. ChemMedChem 2020;15:1163-74. [PMID: 32348628 DOI: 10.1002/cmdc.202000149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
16 He J, Wang S, Liu X, Lin R, Deng F, Jia Z, Zhang C, Li Z, Zhu H, Tang L, Yang P, He D, Jia Q, Zhang Y. Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group. Front Chem 2020;8:256. [PMID: 32351936 DOI: 10.3389/fchem.2020.00256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wong LW, Chong YS, Wong WLE, Sajikumar S. Inhibition of Histone Deacetylase Reinstates Hippocampus-Dependent Long-Term Synaptic Plasticity and Associative Memory in Sleep-Deprived Mice. Cereb Cortex 2020;30:4169-82. [PMID: 32188968 DOI: 10.1093/cercor/bhaa041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
18 Ge D, Han L, Yang F, Zhao N, Yang Y, Zhang H, Chen Y. Development of hydroxamate-based histone deacetylase inhibitors of bis-substituted aromatic amides with antitumor activities. Medchemcomm 2019;10:1828-37. [PMID: 32180916 DOI: 10.1039/c9md00306a] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Rabal O, Sánchez-Arias JA, Cuadrado-Tejedor M, de Miguel I, Pérez-González M, García-Barroso C, Ugarte A, Estella-Hermoso de Mendoza A, Sáez E, Espelosin M, Ursua S, Tan H, Wu W, Xu M, Pineda-Lucena A, Garcia-Osta A, Oyarzabal J. Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles. ACS Chem Neurosci 2019;10:4076-101. [PMID: 31441641 DOI: 10.1021/acschemneuro.9b00303] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
20 Nam G, Jung JM, Park H, Baek SY, Baek KS, Mok HY, Kim DE, Jung YH. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors. Bioorganic & Medicinal Chemistry 2019;27:3408-20. [DOI: 10.1016/j.bmc.2019.06.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
21 Aboukhatwa SM, Hanigan TW, Taha TY, Neerasa J, Ranjan R, El-Bastawissy EE, Elkersh MA, El-Moselhy TF, Frasor J, Mahmud N, McLachlan A, Petukhov PA. Structurally Diverse Histone Deacetylase Photoreactive Probes: Design, Synthesis, and Photolabeling Studies in Live Cells and Tissue. ChemMedChem 2019;14:1096-107. [PMID: 30921497 DOI: 10.1002/cmdc.201900114] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
22 Yang F, Zhao N, Ge D, Chen Y. Next-generation of selective histone deacetylase inhibitors. RSC Adv 2019;9:19571-83. [DOI: 10.1039/c9ra02985k] [Cited by in Crossref: 33] [Article Influence: 11.0] [Reference Citation Analysis]
23 Méndez C, Ledger S, Petoumenos K, Ahlenstiel C, Kelleher AD. RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency. Retrovirology 2018;15:67. [PMID: 30286764 DOI: 10.1186/s12977-018-0451-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
24 Pinheiro PDSM, Rodrigues DA, Sant'anna CMR, Fraga CAM. Modeling zinc-oxygen coordination in histone deacetylase: A comparison of semiempirical methods performance. Int J Quantum Chem 2018;118:e25720. [DOI: 10.1002/qua.25720] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Létévé M, Gonzalez C, Moroy G, Martinez A, Jeanblanc J, Legastelois R, Naassila M, Sapi J, Bourguet E. Unexpected effect of cyclodepsipeptides bearing a sulfonylhydrazide moiety towards histone deacetylase activity. Bioorg Chem 2018;81:222-33. [PMID: 30153587 DOI: 10.1016/j.bioorg.2018.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Wu CP, Hsieh YJ, Murakami M, Vahedi S, Hsiao SH, Yeh N, Chou AW, Li YQ, Wu YS, Yu JS, Ambudkar SV. Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. Biochem Pharmacol 2018;155:316-25. [PMID: 30028995 DOI: 10.1016/j.bcp.2018.07.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
27 Tang C, Du Y, Liang Q, Cheng Z, Tian J. Development of a Novel Ferrocenyl Histone Deacetylase Inhibitor for Triple-Negative Breast Cancer Therapy. Organometallics 2018;37:2368-75. [DOI: 10.1021/acs.organomet.8b00354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
28 Martin MW, Lee JY, Lancia DR, Ng PY, Han B, Thomason JR, Lynes MS, Marshall CG, Conti C, Collis A, Morales MA, Doshi K, Rudnitskaya A, Yao L, Zheng X. Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11. Bioorganic & Medicinal Chemistry Letters 2018;28:2143-7. [DOI: 10.1016/j.bmcl.2018.05.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
29 Abdelkarim H, Neelarapu R, Madriaga A, Vaidya AS, Kastrati I, Karumudi B, Wang YT, Taha TY, Thatcher GRJ, Frasor J, Petukhov PA. Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors. ChemMedChem 2017;12:2030-43. [PMID: 29080240 DOI: 10.1002/cmdc.201700449] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
30 Hsieh H, Chuang H, Shen F, Detroja K, Hsin L, Chen C. Targeting breast cancer stem cells by novel HDAC3-selective inhibitors. European Journal of Medicinal Chemistry 2017;140:42-51. [DOI: 10.1016/j.ejmech.2017.08.069] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
31 Uba AI, Yelekçi K. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay. J Biomol Struct Dyn 2018;36:3231-45. [PMID: 28938863 DOI: 10.1080/07391102.2017.1384402] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
32 Ho RH, Chan JCY, Fan H, Kioh DYQ, Lee BW, Chan ECY. In Silico and in Vitro Interactions between Short Chain Fatty Acids and Human Histone Deacetylases. Biochemistry 2017;56:4871-8. [PMID: 28809557 DOI: 10.1021/acs.biochem.7b00508] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Bourguet E, Ozdarska K, Moroy G, Jeanblanc J, Naassila M. Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD). J Med Chem 2018;61:1745-66. [PMID: 28771357 DOI: 10.1021/acs.jmedchem.7b00115] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
34 Ocasio CA, Sansook S, Jones R, Roberts JM, Scott TG, Tsoureas N, Coxhead P, Guille M, Tizzard GJ, Coles SJ, Hochegger H, Bradner JE, Spencer J. Pojamide: An HDAC3-Selective Ferrocene Analogue with Remarkably Enhanced Redox-Triggered Ferrocenium Activity in Cells. Organometallics 2017;36:3276-83. [DOI: 10.1021/acs.organomet.7b00437] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
35 Zhou H, Wang C, Deng T, Tao R, Li W. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies. Journal of Biomolecular Structure and Dynamics 2018;36:1966-78. [DOI: 10.1080/07391102.2017.1344568] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
36 Hsu KC, Liu CY, Lin TE, Hsieh JH, Sung TY, Tseng HJ, Yang JM, Huang WJ. Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach. Sci Rep 2017;7:3228. [PMID: 28607401 DOI: 10.1038/s41598-017-03417-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
37 Lv W, Zhang G, Barinka C, Eubanks JH, Kozikowski AP. Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors. ACS Med Chem Lett 2017;8:510-5. [PMID: 28523102 DOI: 10.1021/acsmedchemlett.7b00012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
38 Cheng-Sánchez I, García-Ruiz C, Guerrero-Vásquez GA, Sarabia F. An Olefin Cross-Metathesis Approach to Depudecin and Stereoisomeric Analogues. J Org Chem 2017;82:4744-57. [PMID: 28397496 DOI: 10.1021/acs.joc.7b00424] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
39 Traoré MDM, Zwick V, Simões-Pires CA, Nurisso A, Issa M, Cuendet M, Maynadier M, Wein S, Vial H, Jamet H, Wong YS. Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6. ACS Omega 2017;2:1550-62. [PMID: 30023639 DOI: 10.1021/acsomega.6b00481] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
40 Abdizadeh T, Kalani MR, Abnous K, Tayarani-Najaran Z, Khashyarmanesh BZ, Abdizadeh R, Ghodsi R, Hadizadeh F. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents. Eur J Med Chem 2017;132:42-62. [PMID: 28340413 DOI: 10.1016/j.ejmech.2017.03.024] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
41 Pham-the H, Casañola-martin G, Diéguez-santana K, Nguyen-hai N, Ngoc N, Vu-duc L, Le-thi-thu H. Quantitative structure–activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries. SAR and QSAR in Environmental Research 2017;28:199-220. [DOI: 10.1080/1062936x.2017.1294198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.6] [Reference Citation Analysis]
42 Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, Scogliamiglio G, Russo D, D'Angelo G, Franco R, Budillon A, Di Gennaro E. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget 2016;7:7715-31. [PMID: 26735339 DOI: 10.18632/oncotarget.6802] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
43 Reddy DR, Ballante F, Zhou NJ, Marshall GR. Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors. Eur J Med Chem 2017;127:531-53. [PMID: 28109947 DOI: 10.1016/j.ejmech.2016.12.032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
44 De vreese R, Galle L, Depetter Y, Franceus J, Desmet T, Van hecke K, Benoy V, Van den bosch L, D'hooghe M. Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold. Chem Eur J 2017;23:128-36. [DOI: 10.1002/chem.201604167] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
45 Yang F, Peng S, Li Y, Su L, Peng Y, Wu J, Chen H, Liu M, Yi Z, Chen Y. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities. Org Biomol Chem 2016;14:1727-35. [PMID: 26732459 DOI: 10.1039/c5ob02250a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
46 Rabal O, Sánchez-arias JA, Cuadrado-tejedor M, de Miguel I, Pérez-gonzález M, García-barroso C, Ugarte A, Estella-hermoso de Mendoza A, Sáez E, Espelosin M, Ursua S, Haizhong T, Wei W, Musheng X, Garcia-osta A, Oyarzabal J. Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease. J Med Chem 2016;59:8967-9004. [DOI: 10.1021/acs.jmedchem.6b00908] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 8.8] [Reference Citation Analysis]
47 Boskovic ZV, Kemp MM, Freedy AM, Viswanathan VS, Pop MS, Fuller JH, Martinez NM, Figueroa Lazú SO, Hong JA, Lewis TA, Calarese D, Love JD, Vetere A, Almo SC, Schreiber SL, Koehler AN. Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile. ACS Chem Biol 2016;11:1844-51. [PMID: 27064299 DOI: 10.1021/acschembio.6b00012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
48 Harty M, Bearne SL. Measuring benzohydroxamate complexation with Mg2+, Mn2+, Co2+, and Ni2+ using isothermal titration calorimetry. J Therm Anal Calorim 2016;123:2573-82. [DOI: 10.1007/s10973-016-5290-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
49 Rodrigues DA, Ferreira-Silva GÀ, Ferreira AC, Fernandes RA, Kwee JK, Sant'Anna CM, Ionta M, Fraga CA. Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors. J Med Chem 2016;59:655-70. [PMID: 26705137 DOI: 10.1021/acs.jmedchem.5b01525] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
50 De Vreese R, Depetter Y, Verhaeghe T, Desmet T, Benoy V, Haeck W, Van Den Bosch L, D′hooghe M. Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors. Org Biomol Chem 2016;14:2537-49. [DOI: 10.1039/c5ob02625c] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
51 Iranshahi M, Chini MG, Masullo M, Sahebkar A, Javidnia A, Chitsazian Yazdi M, Pergola C, Koeberle A, Werz O, Pizza C, Terracciano S, Piacente S, Bifulco G. Can Small Chemical Modifications of Natural Pan-inhibitors Modulate the Biological Selectivity? The Case of Curcumin Prenylated Derivatives Acting as HDAC or mPGES-1 Inhibitors. J Nat Prod 2015;78:2867-79. [DOI: 10.1021/acs.jnatprod.5b00700] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
52 Segretti MC, Vallerini GP, Brochier C, Langley B, Wang L, Hancock WW, Kozikowski AP. Thiol-Based Potent and Selective HDAC6 Inhibitors Promote Tubulin Acetylation and T-Regulatory Cell Suppressive Function. ACS Med Chem Lett 2015;6:1156-61. [PMID: 26617971 DOI: 10.1021/acsmedchemlett.5b00303] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
53 Thaler F, Moretti L, Amici R, Abate A, Colombo A, Carenzi G, Fulco MC, Boggio R, Dondio G, Gagliardi S, Minucci S, Sartori L, Varasi M, Mercurio C. Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors. Eur J Med Chem 2016;108:53-67. [PMID: 26629860 DOI: 10.1016/j.ejmech.2015.11.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
54 Yang Z, Wang T, Wang F, Niu T, Liu Z, Chen X, Long C, Tang M, Cao D, Wang X, Xiang W, Yi Y, Ma L, You J, Chen L. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer. J Med Chem 2016;59:1455-70. [PMID: 26443078 DOI: 10.1021/acs.jmedchem.5b01342] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 9.1] [Reference Citation Analysis]
55 Zhang Y, Xu W. Isoform-selective histone deacetylase inhibitors: the trend and promise of disease treatment. Epigenomics 2015;7:5-7. [PMID: 25687460 DOI: 10.2217/epi.14.62] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
56 Benito E, Urbanke H, Ramachandran B, Barth J, Halder R, Awasthi A, Jain G, Capece V, Burkhardt S, Navarro-Sala M, Nagarajan S, Schütz AL, Johnsen SA, Bonn S, Lührmann R, Dean C, Fischer A. HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models. J Clin Invest 2015;125:3572-84. [PMID: 26280576 DOI: 10.1172/JCI79942] [Cited by in Crossref: 102] [Cited by in F6Publishing: 54] [Article Influence: 14.6] [Reference Citation Analysis]
57 Méndez C, Ahlenstiel CL, Kelleher AD. Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus. World J Virology 2015; 4(3): 219-244 [PMID: 26279984 DOI: 10.5501/wjv.v4.i3.219] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
58 Lin X, Chen W, Qiu Z, Guo L, Zhu W, Li W, Wang Z, Zhang W, Zhang Z, Rong Y, Zhang M, Yu L, Zhong S, Zhao R, Wu X, Wong JC, Tang G. Design and Synthesis of Orally Bioavailable Aminopyrrolidinone Histone Deacetylase 6 Inhibitors. J Med Chem 2015;58:2809-20. [DOI: 10.1021/jm502011f] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
59 Micelli C, Rastelli G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov Today 2015;20:718-35. [PMID: 25687212 DOI: 10.1016/j.drudis.2015.01.007] [Cited by in Crossref: 109] [Cited by in F6Publishing: 93] [Article Influence: 15.6] [Reference Citation Analysis]
60 Hojjat-Farsangi M. Novel and emerging targeted-based cancer therapy agents and methods. Tumour Biol 2015;36:543-56. [PMID: 25663495 DOI: 10.1007/s13277-015-3184-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
61 Castonguay E, White SA, Kagansky A, St-Cyr DJ, Castillo AG, Brugger C, White R, Bonilla C, Spitzer M, Earnshaw WC, Schalch T, Ekwall K, Tyers M, Allshire RC. Panspecies small-molecule disruptors of heterochromatin-mediated transcriptional gene silencing. Mol Cell Biol 2015;35:662-74. [PMID: 25487573 DOI: 10.1128/MCB.01102-14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Yang F, Zhang T, Wu H, Yang Y, Liu N, Chen A, Li Q, Li J, Qin L, Jiang B, Wang X, Pang X, Yi Z, Liu M, Chen Y. Design and Optimization of Novel Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides Bearing Potent Activities against Tumor Growth and Metastasis. J Med Chem 2014;57:9357-69. [DOI: 10.1021/jm5012148] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
63 Giannini G, Vesci L, Battistuzzi G, Vignola D, Milazzo FM, Guglielmi MB, Barbarino M, Santaniello M, Fantò N, Mor M, Rivara S, Pala D, Taddei M, Pisano C, Cabri W. ST7612AA1, a Thioacetate-ω(γ-lactam carboxamide) Derivative Selected from a Novel Generation of Oral HDAC Inhibitors. J Med Chem 2014;57:8358-77. [DOI: 10.1021/jm5008209] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
64 Di Giorgio E, Gagliostro E, Brancolini C. Selective class IIa HDAC inhibitors: myth or reality. Cell Mol Life Sci 2015;72:73-86. [PMID: 25189628 DOI: 10.1007/s00018-014-1727-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
65 Smyth LJ, Duffy S, Maxwell AP, McKnight AJ. Genetic and epigenetic factors influencing chronic kidney disease. Am J Physiol Renal Physiol 2014;307:F757-76. [PMID: 25080522 DOI: 10.1152/ajprenal.00306.2014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
66 Peedicayil J. Epigenetic approaches for bipolar disorder drug discovery. Expert Opinion on Drug Discovery 2014;9:917-30. [DOI: 10.1517/17460441.2014.922537] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
67 Basmadjian C, Zhao Q, Bentouhami E, Djehal A, Nebigil CG, Johnson RA, Serova M, de Gramont A, Faivre S, Raymond E. Cancer wars: natural products strike back. Front Chem. 2014;2:20. [PMID: 24822174 DOI: 10.3389/fchem.2014.00020] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 7.8] [Reference Citation Analysis]